Sa'ad T Abdullahi1,2, Adeniyi Olagunju1,3, Julius O Soyinka1, Rahman A Bolarinwa4, Olusola J Olarewaju4, Moji T Bakare-Odunola2, Andrew Owen3, Saye Khoo3. 1. Department of Pharmaceutical Chemistry, Obafemi Awolowo University, Ile-Ife, Nigeria. 2. Department of Pharmaceutical and Medicinal Chemistry, University of Ilorin, Ilorin, Nigeria. 3. Department of Molecular and Clinical Pharmacology, University of Liverpool, 70 Pembroke Place, Liverpool, L69 3GF, UK. 4. Department of Haematology, Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria.
Abstract
AIMS: In this study the influence of first-line antimalarial drug artemether-lumefantrine on the pharmacokinetics of the antiretroviral drug nevirapine was investigated in the context of selected single nucleotide polymorphisms (SNPs) in a cohort of adult HIV-infected Nigerian patients. METHODS: This was a two-period, single sequence crossover study. In stage 1, 150 HIV-infected patients receiving nevirapine-based antiretroviral regimens were enrolled and genotyped for seven SNPs. Sparse pharmacokinetic sampling was conducted to identify SNPs independently associated with nevirapine plasma concentration. Patients were categorized as poor, intermediate and extensive metabolizers based on the numbers of alleles of significantly associated SNPs. Intensive sampling was conducted in selected patients from each group. In stage 2, patients received standard artemether-lumefantrine treatment with nevirapine, and intensive pharmacokinetic sampling was conducted on day 3. RESULTS: No clinically significant changes were observed in key nevirapine pharmacokinetic parameters, the 90% confidence interval for the measured changes falling completely within the 0.80-1.25 no-effect boundaries. However, the number of patients with trough plasma nevirapine concentration below the 3400 ng ml-1 minimum effective concentration increased from 10% without artemether-lumefantrine (all extensive metabolizers) to 21% with artemether-lumefantrine (14% extensive, 4% intermediate, and 3% poor metabolizers). CONCLUSIONS: This approach highlights additional increase in the already existing risk of suboptimal trough plasma concentration, especially in extensive metabolizers when nevirapine is co-administered with artemether-lumefantrine.
AIMS: In this study the influence of first-line antimalarial drug artemether-lumefantrine on the pharmacokinetics of the antiretroviral drug nevirapine was investigated in the context of selected single nucleotide polymorphisms (SNPs) in a cohort of adult HIV-infected Nigerian patients. METHODS: This was a two-period, single sequence crossover study. In stage 1, 150 HIV-infectedpatients receiving nevirapine-based antiretroviral regimens were enrolled and genotyped for seven SNPs. Sparse pharmacokinetic sampling was conducted to identify SNPs independently associated with nevirapine plasma concentration. Patients were categorized as poor, intermediate and extensive metabolizers based on the numbers of alleles of significantly associated SNPs. Intensive sampling was conducted in selected patients from each group. In stage 2, patients received standard artemether-lumefantrine treatment with nevirapine, and intensive pharmacokinetic sampling was conducted on day 3. RESULTS: No clinically significant changes were observed in key nevirapine pharmacokinetic parameters, the 90% confidence interval for the measured changes falling completely within the 0.80-1.25 no-effect boundaries. However, the number of patients with trough plasma nevirapine concentration below the 3400 ng ml-1 minimum effective concentration increased from 10% without artemether-lumefantrine (all extensive metabolizers) to 21% with artemether-lumefantrine (14% extensive, 4% intermediate, and 3% poor metabolizers). CONCLUSIONS: This approach highlights additional increase in the already existing risk of suboptimal trough plasma concentration, especially in extensive metabolizers when nevirapine is co-administered with artemether-lumefantrine.
Authors: Sunil Parikh; Fatai Fehintola; Liusheng Huang; Alexander Olson; Waheed A Adedeji; Kristin M Darin; Gene D Morse; Robert L Murphy; Babafemi O Taiwo; Olusegun O Akinyinka; Isaac F Adewole; Francesca T Aweeka; Kimberly K Scarsi Journal: Antimicrob Agents Chemother Date: 2015-09-21 Impact factor: 5.191
Authors: S R Penzak; G Kabuye; P Mugyenyi; F Mbamanya; V Natarajan; R M Alfaro; C Kityo; E Formentini; H Masur Journal: HIV Med Date: 2007-03 Impact factor: 3.180
Authors: Vishal Lamba; Jatinder Lamba; Kazuto Yasuda; Stephen Strom; Julio Davila; Michael L Hancock; James D Fackenthal; Peter K Rogan; Barbara Ring; Steven A Wrighton; Erin G Schuetz Journal: J Pharmacol Exp Ther Date: 2003-10-09 Impact factor: 4.030
Authors: Stephen Ph Alexander; John A Cidlowski; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2017-12 Impact factor: 8.739
Authors: Matthew E Cairns; Patrick G T Walker; Lucy C Okell; Jamie T Griffin; Tini Garske; Kwaku Poku Asante; Seth Owusu-Agyei; Diadier Diallo; Alassane Dicko; Badara Cisse; Brian M Greenwood; Daniel Chandramohan; Azra C Ghani; Paul J Milligan Journal: Malar J Date: 2015-08-19 Impact factor: 2.979
Authors: Sa'ad T Abdullahi; Julius O Soyinka; Adeniyi Olagunju; Rahman A Bolarinwa; Olusola J Olarewaju; Moji T Bakare-Odunola; Markus Winterberg; Joel Tarning; Andrew Owen; Saye Khoo Journal: Antimicrob Agents Chemother Date: 2020-02-21 Impact factor: 5.191